Aileron Therapeutics Inc
Aileron Therapeutics, Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). Its second product candidate is LTI-01, a proenzyme that ha… Read more
Aileron Therapeutics Inc (ALRN) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2024: -0.076x
Based on the latest financial reports, Aileron Therapeutics Inc (ALRN) has a cash flow conversion efficiency ratio of -0.076x as of September 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.82 Million) by net assets ($50.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Aileron Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2014–2023)
This chart illustrates how Aileron Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Aileron Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aileron Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kjell Group AB
ST:KJELL
|
0.245x |
|
AVE S.A.
AT:AVE
|
-1.291x |
|
OPAL Fuels Inc
NASDAQ:OPAL
|
0.038x |
|
Northfield Capital Corporation
V:NFD-A
|
0.002x |
|
Mercator Medical S.A.
WAR:MRC
|
0.052x |
|
Goodness Growth Holdings Inc
OTCQX:GDNSF
|
-0.028x |
|
Senstar Technologies Ltd
NASDAQ:SNT
|
0.009x |
|
Uniquest
KO:077500
|
-0.059x |
Annual Cash Flow Conversion Efficiency for Aileron Therapeutics Inc (2014–2023)
The table below shows the annual cash flow conversion efficiency of Aileron Therapeutics Inc from 2014 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $6.89 Million | $-19.81 Million | -2.876x | -115.41% |
| 2022-12-31 | $18.62 Million | $-24.86 Million | -1.335x | -146.78% |
| 2021-12-31 | $43.90 Million | $-23.75 Million | -0.541x | +67.86% |
| 2020-12-31 | $12.16 Million | $-20.48 Million | -1.684x | -2.06% |
| 2019-12-31 | $16.05 Million | $-26.47 Million | -1.650x | -15.78% |
| 2018-12-31 | $19.60 Million | $-27.93 Million | -1.425x | -231.70% |
| 2017-12-31 | $47.80 Million | $-20.53 Million | -0.430x | -419.87% |
| 2016-12-31 | $-111.81 Million | $-15.01 Million | 0.134x | +8.16% |
| 2015-12-31 | $-94.32 Million | $-11.71 Million | 0.124x | +111.21% |
| 2014-12-31 | $15.57 Million | $-17.23 Million | -1.107x | -- |